Domperidone: an alternative to metoclopramide

1988 ◽  
Vol 26 (15) ◽  
pp. 59-60

The anti-emetic drug domperidone (Motilium - Janssen) was introduced in 1982.1 Like metoclopramide the drug blocks dopamine receptors in the medullary chemoreceptor trigger zone, thereby influencing the central control of nausea and vomiting, and in the gut to increase gastrointestinal motility.2 Parenteral domperidone which was used to prevent vomiting caused by cytotoxic drugs or postoperatively was withdrawn in 1984 because ventricular arrhythmias had followed high intravenous doses.3,4 Oral and rectal domperidone continue to be promoted, especially since the arrival of a second brand (Evoxin - Sterling). The tablets and suppositories are licensed ‘for the treatment of acute nausea and vomiting of any aetiology, in adults’ - a remarkably broad indication. The suppositories are also for children receiving cytotoxic drugs or radiotherapy.

Author(s):  
Stevan R. Emmett ◽  
Nicola Hill ◽  
Federico Dajas-Bailador

Nausea and vomiting can be defined, respectively, as the urge to or the actual act of expelling undigested food from the stomach. It is thought to be an evolutionary defence mechanism to protect against toxic insult (drugs or mi­crobes) and over- eating, while it can also be triggered during pregnancy, or by unpleasant sights or smells. In some instances, it may be the symptom of a more severe underlying pathology. Severity of nausea and vomiting varies considerably between individuals exposed to the same stimulus and symptoms can be highly detrimental to patient quality of life affecting not only their nutritional intake, but also mood and well- being. Although nausea itself is a subjective term, vomiting is a pathophysiological reflex triggered by the vomiting centre located in the medulla. The vomiting centre re­ceives signals from a number of afferent inputs, i.e. the chemoreceptor trigger zone (CTZ), vestibular nucleus, ab­dominal and cardiac vagal afferents, and cerebral cortex (Table 6.1). It may also be activated by hormonal triggers, which accounts for hyperemesis in pregnancy, and the increased incidence of nausea and vomiting associated with the female gender. As the vomiting centre is located close to centres responsible for salivation and breathing, vomiting is often associated with hypersalivation and hyperventilation. The CTZ is highly vascularized and lo­cated at the floor of the fourth ventricle, just outside the blood– brain barrier and, therefore, is itself directly sensi­tive to chemical stimuli. Afferent inputs activate the vomiting centre through several known neurotransmitter pathways; dopamine (D<sub>2</sub>), serotonin (5- HT<sub>3</sub>, 5- HT<sub>4</sub>), acetylcholine (ACh), and substance P (neurokinin 1; NK<sub>1</sub>). Each of which provides a potential pharmacological target in the management of nausea and vomiting, once the cause has been established. Efferent pathways from the vomiting centre induce autonomic changes, including vasoconstriction, pallor, tachycardia, salivation, sweating, and relaxation of the lower oesophagus and fundus of the stomach. In vomiting, oesophageal relaxation leads to contraction of the pyloric sphincter, thereby emptying the contents of the jejunum, duodenum, and pyloric stomach into the relaxed fundus. Coordination of muscle contraction occurs within the dia­phragm and abdomen, and retrograde contractions from the intestine then expel the contents of the fundus.


2018 ◽  
Vol 3 ◽  
pp. 123 ◽  
Author(s):  
Clive J. Petry ◽  
Ken K. Ong ◽  
Keith A. Burling ◽  
Peter Barker ◽  
Sandra F. Goodburn ◽  
...  

Background: Although nausea and vomiting are very common in pregnancy, their pathogenesis is poorly understood. We tested the hypothesis that circulating growth and differentiation factor 15 (GDF15) concentrations in early pregnancy, whose gene is implicated in hyperemesis gravidarum, are associated with nausea and vomiting. Methods: Blood samples for the measurement of GDF15 and human chorionic gonadotrophin (hCG) concentrations were obtained early in the second trimester (median 15.1 (interquartile range 14.4-15.7) weeks) of pregnancy from 791 women from the Cambridge Baby Growth Study, a prospective pregnancy and birth cohort. During each trimester participants completed a questionnaire which included questions about nausea, vomiting and antiemetic use. Associations with pre-pregnancy body mass indexes (BMI) were validated in 231 pregnant NIPTeR Study participants. Results: Circulating GDF15 concentrations were higher in women reporting vomiting in the second trimester than in women reporting no pregnancy nausea or vomiting: 11,581 (10,977-12,219) (n=175) vs. 10,593 (10,066-11,147) (n=193) pg/mL, p=0.02). In women who took antiemetic drugs during pregnancy (n=11) the GDF15 levels were also raised 13,157 (10,558-16,394) pg/mL (p =0.04). Serum GFD15 concentrations were strongly positively correlated with hCG levels but were inversely correlated with maternal BMIs, a finding replicated in the NIPTeR Study. Conclusions: Week 15 serum GDF15 concentrations are positively associated with second trimester vomiting and maternal antiemetic use in pregnancy. Given GDF15’s site of action in the chemoreceptor trigger zone of the brainstem and its genetic associations with hyperemesis gravidarum, these data support the concept that GDF15 may be playing a pathogenic role in pregnancy-associated vomiting.


Author(s):  
Ganesh kumar Gudas ◽  
Manasa B ◽  
Senthil Kumaran K ◽  
Rajesham V V ◽  
Kiran Kumar S ◽  
...  

Promethazine.HCl is a potent anti-emetic. The central antimuscarinic actions of antihistamines are probably responsible for their anti-emetic effects. Promethazine is also believed to inhibit the medullary chemoreceptor trigger zone, and antagonize apomorphine -induced vomiting. Fast dissolving tablets of Promethazine.HCl were prepared using five superdisintegrants viz; sodium starch glycolate, crospovidone, croscarmellose, L-HPC and pregelatinised starch. The precompression blend was tested for angle of repose, bulk density, tapped density, compressibility index and Hausner’s ratio. The tablets were evaluated for weight variation, hardness, friability, disintegration time (1 min), dissolution rate, content uniformity, and were found to be within standard limit. It was concluded that the fast dissolving tablets with proper hardness, rapidly disintegrating with enhanced dissolution can be made using selected superdisintegrants. Among the different formulations of Promethazine.HCl was prepared and studied and the formulation S2 containing crospovidone, mannitol and microcrystalline cellulose combination was found to be the fast dissolving formulation. In the present study an attempt has been made to prepare fast dissolving tablets of Promethazine.HCl, by using different superdisintegrants with enhanced disintegration and dissolution rate. 


Neuron ◽  
2021 ◽  
Vol 109 (3) ◽  
pp. 391-393
Author(s):  
Wenfei Han ◽  
Ivan E. de Araujo

PEDIATRICS ◽  
1967 ◽  
Vol 39 (5) ◽  
pp. 771-774
Author(s):  
J. M. GUPTA ◽  
F. H. LOVEJOY

Twenty patients with phenothiazine toxicity admitted to the Children's Hospital Medical Center have been reviewed. In any patient presenting with bizarre neurological symptoms, phenothiazine toxicity should be borne in mind. Diphenhydramine (Benadryl) was found to be useful in both diagnosis and treatment. The use of phenothiazines in the treatment of acute nausea and vomiting in childhood is questioned.


1992 ◽  
Vol 30 (6) ◽  
pp. 21-23

Nausea and vomiting are very common within a few hours of administration of cytotoxic drugs, and may be severe enough to interrupt treatment or interfere with nutrition. The resulting dehydration may exacerbate toxic effects of the drugs. Ondansetron (Zofran – Glaxo) is an important new type of drug for the prevention of vomiting and nausea induced by chemotherapy and radiotherapy.


BMJ ◽  
1985 ◽  
Vol 290 (6476) ◽  
pp. 1212-1213
Author(s):  
S G Allan ◽  
E J Bayliss ◽  
P S Warrington ◽  
R C F Leonard

1958 ◽  
Vol 192 (2) ◽  
pp. 410-416 ◽  
Author(s):  
H. L. Borison ◽  
E. D. Brand ◽  
R. K. Orkand

The early emetic response (within 4 hr.) after intravenous injection of the nitrogen mustard, methyl-bis (beta-chlorethyl) amine hydrochloride, was compared in dogs and cats. The emetic effect of the drug in dogs differed from that in cats in the following respects: a) the dose of 0.5 mg/kg was uniformly effective in dogs whereas the lowest uniformly effective dose in cats was 5.0 mg/kg. b) Dogs were completely protected against the emetic effect, up to 10.0 mg/kg, by chronic ablation of the medullary emetic chemoreceptor trigger zone (CT zone), whereas cats were not. Cats were completely protected against the emetic effect by abdominal deafferentation accomplished by transthoracic vagotomy in combination with either spinal cord transection at T4 or dorsal rhizotomy of spinal segments T5 to T10. The dose-response curve for emesis after nitrogen mustard in the cat was shifted towards a higher dose level by acute decerebration. A forebrain facilitatory role was further supported by a protective effect, against the mustard-induced vomiting, afforded by chronic frontal lobectomy in the cat. Attention is directed to the similarity in emetic actions of nitrogen mustard and x-radiation, including parallel species differences between dogs and cats.


Sign in / Sign up

Export Citation Format

Share Document